The combination of intravenous pamidronate or zoledronate and IL-2 for lymphoma, myeloma and prostate cancer was generally well tolerated but with side effects including fever, chills and transient flu-like symptoms (Wilhelm et al, 2003; Dieli et al, 2007) Adoptively transferred ex vivo expanded autologous Vγ9Vδ2 T cells with IL-2 also have limited toxicity, the most frequent adverse event being fever and general fatigue (Kobayashi et al, 2007; Bennouna et al, 2008; Abe et al, 2009). This evidence concerns the gene IL2 and lymphoma.